Company Overview - LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company focused on developing and commercializing the first and only aceclidine-based eye drop aimed at improving near vision in individuals with presbyopia [5] - The product candidate, LNZ100, is a preservative-free, single-use, once-daily eye drop containing aceclidine, which has been evaluated in the Phase 3 CLARITY study [5] - Presbyopia affects an estimated 1.8 billion people globally, including 128 million in the United States [5] - The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100 [5] Upcoming Investor Conferences - Company management will participate in the Jefferies London Healthcare Conference from November 19th to November 21st, 2024, with one-on-one meetings scheduled [1] - Management is scheduled for a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3rd, 2024, at 3:30 PM ET, along with one-on-one meetings [2] - At the 7th Annual Evercore HealthCONx Conference on December 4th, 2024, management will also participate in a fireside chat at 7:30 AM ET and one-on-one meetings [2] - Management will take part in a panel discussion titled "Eyes Wide Open on Ophthalmology" at the Citi 2024 Global Healthcare Conference on December 5th, 2024, at 1:45 PM ET, along with one-on-one meetings [3] Webcast Information - A live audio webcast of the Piper Sandler Healthcare Conference fireside chat will be available on the LENZ Therapeutics website, with a replay accessible for 12 months following the event [4]
LENZ Therapeutics to Participate in Upcoming Investor Conferences